EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all continuing into open- label treatment period; data readout anticipated in Q3 2027 followed by the planned U.S. NDA submission in H2 2027– –Successful FDA meeting to align on U.S. NDA submission: Changes in cognition and behavior, a ke ...